Elite Life Management’s AbbVie ABBV Stock Holding History

Elite Life Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$285K	Buy	1,157 +4	+0.3%	+$861	0.33%	40
2026 Q1	$232K	Buy	+1,153	New	+$256K	0.29%	47

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Elite Life Management's ABBV Position: Q2 2026 in Review

Elite Life Management increased its AbbVie (ABBV) stake by 0.35% in Q2 2026, buying an estimated $861 and bringing the position to 1,157 shares worth $285K. The position accounts for 0.33% of the portfolio, ranked #40.

Elite Life Management first reported a position in ABBV in Q1 2026 and has held it in 2 quarters since. 4,189 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Elite Life Management held 1,157 shares of AbbVie worth $285K as of Q2 2026.
Elite Life Management bought 4 AbbVie shares in Q2 2026, an estimated $861.
AbbVie made up 0.33% of Elite Life Management's portfolio in Q2 2026, its #40 holding.
Elite Life Management first reported a position in AbbVie in Q1 2026 and has held it in 2 quarters since.
4,189 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Elite Life Management's 13F filing for Q2 2026, filed 6 Aug 2026.